Transgenic Group Inc. (TYO:2342)

Market Cap	4.26B +11.3%
Revenue (ttm)	13.64B +2.4%
Net Income	33.00M
EPS	1.98
Shares Out	16.65M
PE Ratio	129.19
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,600
Open	252.00
Previous Close	251.00
Day's Range	252.00 - 258.00
52-Week Range	182.00 - 487.00
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Transgenic Group

Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides analysis of the function of individual genes in individuals, elucidation of the relationship between genes and pathology, production of disease model mice, gene expression analysis, and antibody production; clinical trials for pharmaceutical agents, such as bioequivalence studies; administrative services for clinic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 227
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2342

Financial Performance

In fiscal year 2026, Transgenic Group's revenue was 13.17 billion, an increase of 1.30% compared to the previous year's 13.01 billion. Losses were -77.00 million, -92.93% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error